> ## Content Index
> Fetch the complete content index at: https://adjacent.media/llms.txt
> Use this file to discover other available public pages before exploring further.

# AI's Uneven Takeover of Drug Development
- URL: https://adjacent.media/signals/ais-uneven-takeover-of-drug-development/
- Published: 2026-06-17T16:13:54.000Z
- Updated: 2026-06-17T16:13:54.000Z
- Description: Andreessen Horowitz identifies a bifurcated path in AI adoption across pharma. Software-native processes—computational screening, molecular modeling—are experiencing exponential gains.
- Author: Jonathan Greene
- Tags: #signal, theme-ai, AI & ML

Source: [a16z](https://open.substack.com/pub/a16z/p/uneven-frontiers)

Andreessen Horowitz identifies a bifurcated path in AI adoption across pharma. Software-native processes—computational screening, molecular modeling—are experiencing exponential gains. Clinical trials and regulatory approval remain locked into slow, human-dependent workflows that no algorithm can meaningfully accelerate. This creates a bottleneck: companies winning on discovery speed will generate promising candidates faster than they can validate them. The competitive advantage isn't better AI. It's the capital and patience to manage a discovery pipeline moving at speed while development remains constrained by biology and regulation.